KMPH
Undervalued by 485.7% based on the discounted cash flow analysis.
Market cap | $198.06 Million |
---|---|
Enterprise Value | - |
Dividend Yield | $0.0 (0.0%) |
Earnings per Share | $0.0 |
Beta | 0.78 |
Outstanding Shares | 34,504,862 |
Avg 30 Day Volume | 137,517 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 0.0 |
---|---|
PEG | - |
Price to Sales | - |
Price to Book Ratio | - |
Enterprise Value to Revenue | - |
Enterprise Value to EBIT | - |
Enterprise Value to Net Income | - |
Total Debt to Enterprise | - |
Debt to Equity | - |
No data
No data
KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT™ (Ligand Activated Therapy) technology. KemPharm utilizes its...